ArticleMedicine2026
A case report of combined oxidative phosphorylation deficiency 35 (COXPD35) in Palestine caused by novel compound heterozygous TRIT1 variants.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCombined oxidative phosphorylation deficiency 35 (COXPD35) is an extremely rare mitochondrial disorder inherited in an autosomal recessive pattern. It results from pathogenic variants in the TRIT1 gene, leading to hypomodified cytosolic and mitochondrial tRNAs. We report the first identified case of COXPD35 in Palestine, resulting from 2 novel variants of the TRIT1 gene. PATIENT CONCERNS: A 2-year-and-6-month-old female patient with seizures, neurodevelopmental delay, microcephaly, dysmorphic facial features, abnormal electroencephalogram (EEG), and thinning of the corpus callosum on Brain magnetic resonance imaging, presenting to the Emergency Department with status epilepticus, and right lower lobe pneumonia. DIAGNOSES: Combined oxidative phosphorylation deficiency 35 (COXPD35) caused by 2 novel TRIT1 variants that have never been previously reported in the literature, diagnosed clinically, and were identified by Whole-exome sequencing (WES) and confirmed by Sanger sequencing.
interventionsThe patient received 1 shot of IV diazepam 0.3 mg/kg after IV cannulation, followed by IV ceftriaxone 500 mg twice daily, IV hydrocortisone 20 mg every 4 hours, and albuterol, ipratropium bromide, and hypertonic saline nebulizers regularly. Additionally, she was given intravenous fluids at a rate of 60 mL/h of 5% dextrose saline. She was given a 200 mg dose of phenytoin IV for seizure control. Upon clinical suspicion of a mitochondrial disease, WES was performed, followed by Sanger sequencing for confirmation of the findings. OUTCOMES: The patient clinically improved, with cessation of seizures, recovery from pneumonia, and confirmed diagnosis of COXPD35. LESSONS: The identification of new TRIT1 variants and the expanding phenotypic spectrum of COXPD35 provides insights into its clinical and genotypic characteristics. WES and Sanger Sequencing confirm the diagnosis of COXPD35; however, it can be challenging in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.